Abstract
AimTo determine clinical correlations to intraocular vascular endothelial growth factor A (VEGF-A) suppression times (VSTs) on the treatment of neovascular age-related macular degeneration (nAMD) with ranibizumab (Lucentis) or aflibercept (Eylea).MethodsSeven...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have